GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option

by Vandana Singh, Benzinga Editor

September 28, 2021 9:35 AM | 1 min read |

The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for pre-exposure prophylaxis (PrEP).
The priority review designation sets ViiV up for a decision from the agency by January 24, 2022.
If approved, it'd be the first long-acting PrEP drug and would challenge medicines from Gilead Sciences Inc GILD.
ViiV Healthcare is a joint venture between GlaxoSmithKline plc GSK, Pfizer Inc PFE, and Shionogi.
ViiV Healthcare will initiate submissions of cabotegravir long-acting for PrEP to other regulatory authorities by the end of 2021
Related content: Benzinga's Full FDA Calendar.
Price Action: PFE stock is down 1.77% at $42.80, and GSK stock is down 0.94% at $38.14 during the market session on the last check Tuesday.

Posted In: Biotech News Health Care FDA Movers Trading Ideas General Briefs HIV treatment

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.